Real-world evaluation of compliance and preference in Alzheimer’s disease treatment: An observational study in Taiwan

Tzu Hsien Lai, Wen Fu Wang, Bak Sau Yip, Yu Wan Yang, Giia Sheun Peng, Shih Jei Tsai, Yi Chu Liao, Ming Chyi Pai

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: Among the medications approved for Alzheimer’s disease (AD), rivastigmine is the only one available as transdermal patch. The aim of this study was to evaluate compliance and caregivers’ preference with oral and transdermal (rivastigmine) monotherapy in patients with mild-to-moderate AD from Taiwan. Methods: Real-world Evaluation of Compliance And Preference in Alzheimer’s disease treatment (RECAP) in Taiwan was a prospective, noninterventional, observational study with a 24-week (±8 weeks) observational period for each participant. Eligible patients were grouped into one of the two treatment cohorts based on the baseline AD therapy: oral (donepezil, galantamine, rivastigmine, or memantine) or transdermal (rivastigmine patch). The primary end points were caregiver preference and caregiver assessment of patients’ compliance to the current medication (oral or transdermal medication) at Week 24 (end of the study). Safety was assessed by recording any adverse events. Results: A total of 301 patients (age: 77.6±7.19 years) were enrolled from nine centers in Taiwan, of whom 138 (45.8%) patients were in the transdermal monotherapy cohort. Caregivers of patients who were exposed to both forms of therapies demonstrated a higher preference for transdermal rivastigmine monotherapy than the oral monotherapy (82.4% [n=61] versus 17.6% [n=13], P<0.0001); for patients treated with only one therapy, the caregivers’ preference was significantly in favor of the treatment to which the patient was exposed (both P<0.0001). In both cohorts, patients showed good compliance, with an overall score of 8.65±1.38 on an 11-point scale. Of 301 enrolled patients, 102 (33.9%) reported at least one adverse event during the study (51 patients each in the two cohorts). Conclusion: With the higher caregiver preference and a good patient compliance, the transdermal rivastigmine patch is a suitable treatment choice for patients with mild-to-moderate AD, especially for patients intolerant to oral therapies.

Original languageEnglish
Pages (from-to)383-390
Number of pages8
JournalPatient Preference and Adherence
Volume10
DOIs
Publication statusPublished - 2016 Mar 30

Fingerprint

Rivastigmine
Taiwan
dementia
Compliance
Observational Studies
caregiver
Alzheimer Disease
evaluation
Caregivers
medication
Transdermal Patch
Therapeutics
event
Patient Compliance
recording
Galantamine
Memantine

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Social Sciences (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Health Policy

Cite this

Lai, Tzu Hsien ; Wang, Wen Fu ; Yip, Bak Sau ; Yang, Yu Wan ; Peng, Giia Sheun ; Tsai, Shih Jei ; Liao, Yi Chu ; Pai, Ming Chyi. / Real-world evaluation of compliance and preference in Alzheimer’s disease treatment : An observational study in Taiwan. In: Patient Preference and Adherence. 2016 ; Vol. 10. pp. 383-390.
@article{fbe22e04d9e9409ebd9c8412c7b56b8b,
title = "Real-world evaluation of compliance and preference in Alzheimer’s disease treatment: An observational study in Taiwan",
abstract = "Purpose: Among the medications approved for Alzheimer’s disease (AD), rivastigmine is the only one available as transdermal patch. The aim of this study was to evaluate compliance and caregivers’ preference with oral and transdermal (rivastigmine) monotherapy in patients with mild-to-moderate AD from Taiwan. Methods: Real-world Evaluation of Compliance And Preference in Alzheimer’s disease treatment (RECAP) in Taiwan was a prospective, noninterventional, observational study with a 24-week (±8 weeks) observational period for each participant. Eligible patients were grouped into one of the two treatment cohorts based on the baseline AD therapy: oral (donepezil, galantamine, rivastigmine, or memantine) or transdermal (rivastigmine patch). The primary end points were caregiver preference and caregiver assessment of patients’ compliance to the current medication (oral or transdermal medication) at Week 24 (end of the study). Safety was assessed by recording any adverse events. Results: A total of 301 patients (age: 77.6±7.19 years) were enrolled from nine centers in Taiwan, of whom 138 (45.8{\%}) patients were in the transdermal monotherapy cohort. Caregivers of patients who were exposed to both forms of therapies demonstrated a higher preference for transdermal rivastigmine monotherapy than the oral monotherapy (82.4{\%} [n=61] versus 17.6{\%} [n=13], P<0.0001); for patients treated with only one therapy, the caregivers’ preference was significantly in favor of the treatment to which the patient was exposed (both P<0.0001). In both cohorts, patients showed good compliance, with an overall score of 8.65±1.38 on an 11-point scale. Of 301 enrolled patients, 102 (33.9{\%}) reported at least one adverse event during the study (51 patients each in the two cohorts). Conclusion: With the higher caregiver preference and a good patient compliance, the transdermal rivastigmine patch is a suitable treatment choice for patients with mild-to-moderate AD, especially for patients intolerant to oral therapies.",
author = "Lai, {Tzu Hsien} and Wang, {Wen Fu} and Yip, {Bak Sau} and Yang, {Yu Wan} and Peng, {Giia Sheun} and Tsai, {Shih Jei} and Liao, {Yi Chu} and Pai, {Ming Chyi}",
year = "2016",
month = "3",
day = "30",
doi = "10.2147/PPA.S95271",
language = "English",
volume = "10",
pages = "383--390",
journal = "Patient Preference and Adherence",
issn = "1177-889X",
publisher = "Dove Medical Press Ltd.",

}

Real-world evaluation of compliance and preference in Alzheimer’s disease treatment : An observational study in Taiwan. / Lai, Tzu Hsien; Wang, Wen Fu; Yip, Bak Sau; Yang, Yu Wan; Peng, Giia Sheun; Tsai, Shih Jei; Liao, Yi Chu; Pai, Ming Chyi.

In: Patient Preference and Adherence, Vol. 10, 30.03.2016, p. 383-390.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Real-world evaluation of compliance and preference in Alzheimer’s disease treatment

T2 - An observational study in Taiwan

AU - Lai, Tzu Hsien

AU - Wang, Wen Fu

AU - Yip, Bak Sau

AU - Yang, Yu Wan

AU - Peng, Giia Sheun

AU - Tsai, Shih Jei

AU - Liao, Yi Chu

AU - Pai, Ming Chyi

PY - 2016/3/30

Y1 - 2016/3/30

N2 - Purpose: Among the medications approved for Alzheimer’s disease (AD), rivastigmine is the only one available as transdermal patch. The aim of this study was to evaluate compliance and caregivers’ preference with oral and transdermal (rivastigmine) monotherapy in patients with mild-to-moderate AD from Taiwan. Methods: Real-world Evaluation of Compliance And Preference in Alzheimer’s disease treatment (RECAP) in Taiwan was a prospective, noninterventional, observational study with a 24-week (±8 weeks) observational period for each participant. Eligible patients were grouped into one of the two treatment cohorts based on the baseline AD therapy: oral (donepezil, galantamine, rivastigmine, or memantine) or transdermal (rivastigmine patch). The primary end points were caregiver preference and caregiver assessment of patients’ compliance to the current medication (oral or transdermal medication) at Week 24 (end of the study). Safety was assessed by recording any adverse events. Results: A total of 301 patients (age: 77.6±7.19 years) were enrolled from nine centers in Taiwan, of whom 138 (45.8%) patients were in the transdermal monotherapy cohort. Caregivers of patients who were exposed to both forms of therapies demonstrated a higher preference for transdermal rivastigmine monotherapy than the oral monotherapy (82.4% [n=61] versus 17.6% [n=13], P<0.0001); for patients treated with only one therapy, the caregivers’ preference was significantly in favor of the treatment to which the patient was exposed (both P<0.0001). In both cohorts, patients showed good compliance, with an overall score of 8.65±1.38 on an 11-point scale. Of 301 enrolled patients, 102 (33.9%) reported at least one adverse event during the study (51 patients each in the two cohorts). Conclusion: With the higher caregiver preference and a good patient compliance, the transdermal rivastigmine patch is a suitable treatment choice for patients with mild-to-moderate AD, especially for patients intolerant to oral therapies.

AB - Purpose: Among the medications approved for Alzheimer’s disease (AD), rivastigmine is the only one available as transdermal patch. The aim of this study was to evaluate compliance and caregivers’ preference with oral and transdermal (rivastigmine) monotherapy in patients with mild-to-moderate AD from Taiwan. Methods: Real-world Evaluation of Compliance And Preference in Alzheimer’s disease treatment (RECAP) in Taiwan was a prospective, noninterventional, observational study with a 24-week (±8 weeks) observational period for each participant. Eligible patients were grouped into one of the two treatment cohorts based on the baseline AD therapy: oral (donepezil, galantamine, rivastigmine, or memantine) or transdermal (rivastigmine patch). The primary end points were caregiver preference and caregiver assessment of patients’ compliance to the current medication (oral or transdermal medication) at Week 24 (end of the study). Safety was assessed by recording any adverse events. Results: A total of 301 patients (age: 77.6±7.19 years) were enrolled from nine centers in Taiwan, of whom 138 (45.8%) patients were in the transdermal monotherapy cohort. Caregivers of patients who were exposed to both forms of therapies demonstrated a higher preference for transdermal rivastigmine monotherapy than the oral monotherapy (82.4% [n=61] versus 17.6% [n=13], P<0.0001); for patients treated with only one therapy, the caregivers’ preference was significantly in favor of the treatment to which the patient was exposed (both P<0.0001). In both cohorts, patients showed good compliance, with an overall score of 8.65±1.38 on an 11-point scale. Of 301 enrolled patients, 102 (33.9%) reported at least one adverse event during the study (51 patients each in the two cohorts). Conclusion: With the higher caregiver preference and a good patient compliance, the transdermal rivastigmine patch is a suitable treatment choice for patients with mild-to-moderate AD, especially for patients intolerant to oral therapies.

UR - http://www.scopus.com/inward/record.url?scp=84962366928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962366928&partnerID=8YFLogxK

U2 - 10.2147/PPA.S95271

DO - 10.2147/PPA.S95271

M3 - Article

AN - SCOPUS:84962366928

VL - 10

SP - 383

EP - 390

JO - Patient Preference and Adherence

JF - Patient Preference and Adherence

SN - 1177-889X

ER -